Seshadri Neervannan is COO at Tarsus Pharmaceuticals, Inc. (TARS). They have made 6 open-market trades across 1 company since 2023, most recently 2026-09-04.
CIK 0001827584
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 78,532 | $5.4M |
Shares reported on the most recent Form 4, priced at the 2026-09-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | SELL · 10b5-1 | 2026-09-04 | 2026-09-09 | $85.00 | $388K | -5.4% | -10.7% | — |
| TARS | SELL · 10b5-1 | 2026-03-20 | 2026-03-24 | $66.75 | $200K | +9.1% | -5.3% | -1.3% |
| TARS | SELL | 2026-03-17 | 2026-03-19 | $68.21 | $772K | +5.1% | -1.2% | -6.4% |
| TARS | SELL · 10b5-1 | 2026-03-04 | 2026-03-05 | $76.67 | $641K | -5.6% | -5.1% | -20.6% |
| TARS | SELL | 2025-03-18 | 2025-03-20 | $47.89 | $726K | -0.8% | -1.6% | -16.7% |
| TARS | SELL | 2024-03-18 | 2024-03-19 | $30.60 | $299K | +13.2% | +3.7% | -8.9% |
| TARS | SELL | 2023-03-21 | 2023-03-23 | $12.55 | $14K | +3.7% | +21.4% | +52.5% |
| TARS | SELL | 2023-03-17 | 2023-03-21 | $12.94 | $10K | -2.3% | +12.6% | +48.2% |
| TARS | SELL | 2023-03-16 | 2023-03-17 | $13.43 | $5K | -0.9% | -2.4% | +44.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.